Bliss GVS Pharma Limited (NSE:BLISSGVS)
India
· Delayed Price · Currency is INR 149.30
+0.87 (0.59%)
Jun 13, 2025, 3:29 PM IST
Bliss GVS Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 8,097 | 7,702 | 7,516 | 7,475 | 5,772 | Upgrade
|
| Revenue Growth (YoY) | 5.13% | 2.48% | 0.55% | 29.49% | -16.26% | Upgrade
|
| Cost of Revenue | 4,137 | 4,007 | 4,136 | 4,031 | 3,375 | Upgrade
|
| Gross Profit | 3,960 | 3,695 | 3,380 | 3,444 | 2,397 | Upgrade
|
| Selling, General & Admin | 1,121 | 1,394 | 1,160 | 1,045 | 811.69 | Upgrade
|
| Other Operating Expenses | 1,573 | 795.34 | 1,047 | 1,212 | 502.63 | Upgrade
|
| Operating Expenses | 2,988 | 2,453 | 2,394 | 2,431 | 1,502 | Upgrade
|
| Operating Income | 972.66 | 1,242 | 986.49 | 1,013 | 894.47 | Upgrade
|
| Interest Expense | -81.2 | -60.51 | -98.64 | -36.93 | -43.01 | Upgrade
|
| Interest & Investment Income | - | 117.9 | 75.05 | 88.18 | 95.79 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 111.35 | 77.69 | 200.57 | 78.86 | Upgrade
|
| Other Non Operating Income (Expenses) | 364.94 | 44.93 | 16.48 | 14.99 | 15.47 | Upgrade
|
| EBT Excluding Unusual Items | 1,256 | 1,456 | 1,057 | 1,280 | 1,042 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 4.58 | 3.65 | 0.68 | -0.31 | Upgrade
|
| Asset Writedown | - | - | - | -3.06 | - | Upgrade
|
| Other Unusual Items | - | -291.96 | - | -735.95 | - | Upgrade
|
| Pretax Income | 1,256 | 1,169 | 1,061 | 541.65 | 1,041 | Upgrade
|
| Income Tax Expense | 353.84 | 352.94 | 293.37 | 310.39 | 301.55 | Upgrade
|
| Earnings From Continuing Operations | 902.55 | 815.78 | 767.35 | 231.27 | 739.72 | Upgrade
|
| Net Income to Company | 902.55 | 815.78 | 767.35 | 231.27 | 739.72 | Upgrade
|
| Minority Interest in Earnings | -59.56 | -61.24 | -58.76 | -80.86 | -54.81 | Upgrade
|
| Net Income | 842.99 | 754.54 | 708.59 | 150.4 | 684.91 | Upgrade
|
| Net Income to Common | 842.99 | 754.54 | 708.59 | 150.4 | 684.91 | Upgrade
|
| Net Income Growth | 11.72% | 6.49% | 371.13% | -78.04% | -29.58% | Upgrade
|
| Shares Outstanding (Basic) | 105 | 104 | 104 | 103 | 103 | Upgrade
|
| Shares Outstanding (Diluted) | 106 | 106 | 105 | 105 | 105 | Upgrade
|
| Shares Change (YoY) | -0.03% | 0.56% | 0.26% | -0.26% | 2.26% | Upgrade
|
| EPS (Basic) | 8.02 | 7.23 | 6.83 | 1.46 | 6.64 | Upgrade
|
| EPS (Diluted) | 7.95 | 7.11 | 6.72 | 1.43 | 6.49 | Upgrade
|
| EPS Growth | 11.81% | 5.80% | 369.93% | -77.97% | -31.18% | Upgrade
|
| Free Cash Flow | 298.48 | 1,241 | -594.86 | 614.78 | 548.45 | Upgrade
|
| Free Cash Flow Per Share | 2.81 | 11.70 | -5.64 | 5.84 | 5.20 | Upgrade
|
| Dividend Per Share | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | Upgrade
|
| Gross Margin | 48.91% | 47.98% | 44.98% | 46.07% | 41.52% | Upgrade
|
| Operating Margin | 12.01% | 16.13% | 13.13% | 13.55% | 15.50% | Upgrade
|
| Profit Margin | 10.41% | 9.80% | 9.43% | 2.01% | 11.87% | Upgrade
|
| Free Cash Flow Margin | 3.69% | 16.11% | -7.92% | 8.22% | 9.50% | Upgrade
|
| EBITDA | 1,267 | 1,479 | 1,160 | 1,166 | 1,042 | Upgrade
|
| EBITDA Margin | 15.65% | 19.20% | 15.43% | 15.60% | 18.06% | Upgrade
|
| D&A For EBITDA | 294.18 | 236.6 | 173.54 | 152.62 | 147.88 | Upgrade
|
| EBIT | 972.66 | 1,242 | 986.49 | 1,013 | 894.47 | Upgrade
|
| EBIT Margin | 12.01% | 16.13% | 13.13% | 13.55% | 15.50% | Upgrade
|
| Effective Tax Rate | 28.16% | 30.20% | 27.66% | 57.30% | 28.96% | Upgrade
|
| Revenue as Reported | 8,462 | 7,990 | 7,694 | 7,789 | 5,974 | Upgrade
|
| Advertising Expenses | - | 84.27 | 61.7 | 48.05 | 18.17 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.